Gyre Therapeutics, Inc.
DE ˙ DB ˙ US4037831033
5,30 € ↑0,44 (9,05%)
2026-06-05
DEL PRIS
SecurityDE:L9S / Gyre Therapeutics, Inc.
InstitutionGoldman Sachs Group Inc
Latest Disclosed Ownership73,122 shares
Latest Disclosed Value $ 509,660
Goldman Sachs Group Inc reports 135.06% increase in ownership of L9S / Gyre Therapeutics, Inc.

On May 15, 2026 - Goldman Sachs Group Inc filed a 13F-HR form disclosing ownership of 73,122 shares of Gyre Therapeutics, Inc. (DE:L9S) valued at $438,732 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 31,108 shares of Gyre Therapeutics, Inc.. This represents a change in shares of 135.06% during the quarter. The current value of the position is $387,547 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F GYRE THERAPEUTICS CMN 403783103 73,122 42,014 135.06 510 132.42 0.0000
2026-02-10 2025-12-31 13F GYRE THERAPEUTICS CMN 403783103 31,108 13,074 72.50 220 63.43 0.0000
2025-11-14 2025-09-30 13F GYRE THERAPEUTICS CMN 403783103 18,034 18,034 135 0.0000
2025-08-14 2025-06-30 13F GYRE THERAPEUTICS CMN 403783103 0 -16,147 -100.00 0 -100.00
2025-06-27 2025-03-31 13F/A-2 GYRE THERAPEUTICS CMN 403783103 16,147 -10,239 -38.80 125 -61.13 0.0000
2025-05-16 2025-03-31 13F/A-1 GYRE THERAPEUTICS CMN 403783103 16,147 -10,239 125 0.0000
2025-05-09 2025-03-31 13F GYRE THERAPEUTICS CMN 403783103 16,147 -10,239 125 0.0000
2025-02-11 2024-12-31 13F GYRE THERAPEUTICS CMN 403783103 26,386 7,587 40.36 319 35.74 0.0001
2024-11-14 2024-09-30 13F GYRE THERAPEUTICS CMN 403783103 18,799 18,799 236 0.0000
2024-08-13 2024-06-30 13F GYRE THERAPEUTICS CMN 403783103 0 -46,093 -100.00 0 -100.00
2024-05-15 2024-03-31 13F GYRE THERAPEUTICS CMN 403783103 46,093 46,093 806 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.